H.C. Wainwright raised the firm’s price target on Innoviva (INVA) to $46 from $45 and keeps a Buy rating on the shares. The firm says zoliflodacin was approved on schedule.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA:
- Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence
- Innoviva’s Zoliflodacin: A Promising Antibiotic Driving Buy Rating Amidst Urgent Need for Drug-Resistant Infection Solutions
- Innoviva announces Lancet publication of ‘positive’ Zoliflodacin Phase 3 data
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Innoviva Reports Strong Q3 2025 Financial Results